Core Viewpoint - The company anticipates a significant reduction in net loss for the first half of the year, projecting a loss not exceeding RMB 10 million, which represents a decrease of at least 83% compared to the same period last year [1] Group 1: Financial Performance - The expected net loss for the reporting period is projected to be less than RMB 10 million, marking a reduction of no less than 83% [1] - The reduction in net loss is primarily attributed to the sales of the VitaFlow Liberty® transcatheter aortic valve and its delivery system, which have been sold in over 20 countries/regions overseas, resulting in more than a twofold increase in overseas revenue compared to the same period last year [1] Group 2: Product Development and Commercialization - The AnchorMan® left atrial appendage occluder system and its delivery system are making steady progress in commercialization in China, having received CE marking and achieved commercialization in Europe during the reporting period, contributing to revenue growth [1] Group 3: Operational Efficiency - The company has enhanced operational efficiency through continuous optimization of resource allocation and active cost management measures [1] - The company's associate, 4C Medical Technologies, Inc, completed a Series D financing round, resulting in a decrease in the company's equity stake in 4C Medical, which is recognized as a gain from the partial sale of equity [1]

Core Viewpoint - The company expects a net loss of no more than RMB 10 million for the six months ending June 30, 2025, representing a decrease of at least 83% compared to the same period in 2024 [1] Group 1: Financial Performance - The anticipated net loss reduction is primarily attributed to the sales of VitaFlow Liberty® transcatheter aortic valve and its retrievable delivery system in over 20 countries/regions [1] - Revenue from overseas markets has more than doubled compared to the six months ending June 30, 2024 [1] Group 2: Product Development and Commercialization - The AnchorMan® left atrial appendage occluder system and its guiding system are making steady progress in commercialization in China [1] - The company obtained CE marking for the AnchorMan® system and has commenced commercialization in Europe during the reporting period [1] Group 3: Operational Efficiency - The company has implemented measures to optimize resource allocation and actively manage expenses, which have further enhanced operational efficiency [1] - The equity stake in the joint venture 4C Medical has decreased following its completion of Series D financing, resulting in recognized gains from the partial sale of shares [1]

本文源自：金融界AI电报 心通医疗-B(02160.HK)公布，该集团预期2025年上半年取得净亏损不高于人民币1000万元，同比减少不 低于83%。 ...

Core Viewpoint - The company expects a net loss of no more than RMB 10 million for the six months ending June 30, 2025, representing a decrease of at least 83% compared to the same period ending June 30, 2024 [1] Group 1 - The significant reduction in net loss is primarily attributed to the sales of the Vita Flow Liberty transcatheter aortic valve and its delivery system in over 20 countries, resulting in more than a twofold increase in overseas revenue compared to the six months ending June 30, 2024 [1] - The commercial progress of the Anchor Man left atrial appendage occluder system and its delivery system in China has been steady, achieving CE marking and commercialization in Europe during the reporting period, contributing to revenue growth [1] - The company has enhanced operational efficiency through continuous optimization of resource allocation and active cost management measures [1] - The joint venture 4C Medical Technologies, Inc completed a Series D financing round, leading to a decrease in the company's equity stake in 4C Medical, which is recognized as a gain from the partial sale of equity [1]

Core Viewpoint - The company expects to achieve a net loss of no more than RMB 10 million in the first half of 2025, representing a year-on-year reduction of not less than 83% [1] Group 1: Financial Performance - The reduction in net loss is primarily attributed to the sales of VitaFlow Liberty® transcatheter aortic valve and its delivery system in over 20 countries/regions, with overseas revenue increasing by more than two times year-on-year [1] - The commercial progress of the AnchorMan® left atrial appendage occluder system and its guiding system in China is steadily advancing, having obtained CE marking and commercialized in Europe during the reporting period, contributing to revenue growth [1] Group 2: Operational Efficiency - The company has enhanced operational efficiency through continuous optimization of resource allocation and active cost management measures [1] - The company's associate, 4C Medical Technologies, Inc, completed a Series D financing round, resulting in a decrease in the company's equity stake in 4C Medical, which generated income from the sale of part of its equity [1]

微創心通醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 MicroPort CardioFlow Medtech Corporation 股東及潛在投資者於買賣本公司股份時，務請審慎行事。 承董事會命 微創心通醫療科技有限公司 （股份代號：2160） 2025年上半年盈利預告 — 淨虧損大幅減少 本公告乃由微創心通醫療科技有限公司（「本公司」，連同其附屬公司統稱「本 集團」或「我們」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第 13.09條以及香港法例第571章證券及期貨條例第XIVA部的內幕消息條文（定義 見上市規則）發出。 本公司董事會（「董事會」）謹此通知本公司股東（「股東」）及潛在投資者，根據 對本集團截至2025年6月30日止六個月（「報告期」）未經審核管理賬目的初步審 閱及對董事會目前可得最新資料的評估，本集團預期報告期錄得淨虧損不高 於人民幣 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 微创心通医疗科技有限公司 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02160 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.000005 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 10,000,000,000 | USD | | 0.000005 USD | | 50,000 | 本月底法定/註冊股本總額： US ...

Company Overview - MicroPort CardioFlow Medtech Co., Ltd. is a leading innovative medical device company in the field of structural heart disease in China, originating from a valve pre-research project established in 2009 and listed on the Hong Kong Stock Exchange in February 2021 [2] - The company has successfully launched its self-developed transcatheter aortic valve implantation (TAVI) series and related surgical products in over 700 core hospitals across more than 20 countries and regions, treating over 10,000 patients with structural heart disease [2] - The VitaFlow Liberty transcatheter aortic valve and its reusable delivery system became the first domestically developed TAVI system to receive EU CE certification in 2024, accelerating the company's global strategic layout [2] Financial Performance - As of December 31, 2024, MicroPort CardioFlow reported total operating revenue of 362 million yuan, a year-on-year increase of 7.54% [1] - The net profit attributable to the parent company was -49.446 million yuan, showing a significant year-on-year increase of 89.51% [1] - The gross profit margin stood at 69.48%, with a debt-to-asset ratio of 16.97% [1] Market Position and Valuation - Currently, there are no institutional investment ratings for MicroPort CardioFlow [1] - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -2.24 times, with a median of 1.4 times [1] - MicroPort CardioFlow's P/E ratio is -61 times, ranking 61st in the industry, compared to other companies such as Jingjiu Medical (0.38 times), Star Medical Holdings (0.45 times), and others [1]

Group 1 - The Hang Seng Index fell by 0.43%, down 109 points, while the Hang Seng Tech Index dropped by 1.57%. The morning trading volume in Hong Kong stocks was HKD 148.2 billion [1] - The Hang Seng Biotechnology Index rose by 1.77%, with notable gains from MicroPort Medical (00853) up 9.7%, MicroPort NeuroScience (02172) up over 8%, and Innovent Biologics (01801) up 4.85% [1] - WuXi AppTec (02359) increased by 2.24%, WuXi Biologics (02126) rose by 6.5%, and WuXi Biologics (02269) saw an increase of over 3% after announcing the construction of a modular biomanufacturing facility in Singapore [1] Group 2 - Mindray Medical-B (02160) surged by 8.8% as the company is expected to acquire and restructure the MicroPort cardiac rhythm management business, enhancing its product pipeline [2] - Insurance stocks continued to rise, with New China Life Insurance (01336) up 4.47% and China Life Insurance (02628) increasing by 1.5% [3] Group 3 - 361 Degrees (01361) rose by 6.5%, with the company showing steady revenue growth, and institutions expect strong revenue growth for the full year [4] - Dreamscape (01119) increased by 3.5% after signing a capitalization agreement with Playrix, bringing in a long-term strategic partner [5] Group 4 - GAC Group-B (01167) surged over 20% as a concerted action party increased its holdings by over 60,000 shares, raising its stake to 25.36% [6] - Semiconductor stocks collectively declined, with Hua Hong Semiconductor (01347) down 5.3%, SMIC (00981) down 3.9%, and ASMPT (00522) down 2.74% [6]

Market Overview - The Hang Seng Index fell by 0.43%, down 109 points, while the Hang Seng Tech Index decreased by 1.57%. The early trading volume in Hong Kong stocks was HKD 148.2 billion [1]. Biotechnology Sector - The Hang Seng Biotechnology Index rose by 1.77%. Notable gainers included MicroPort Medical (00853) up 9.7%, MicroPort NeuroTech (02172) up over 8%, and Innovent Biologics (01801) up 4.85% [1]. - WuXi AppTec (02359) increased by 2.24%, WuXi Biologics (02126) rose by 6.5%, and WuXi Biologics (02269) saw an increase of over 3% following the announcement of the construction of a modular biologics manufacturing facility in Singapore [1]. - Fosun Pharma (02196) gained over 5% after acquiring exclusive rights for the innovative Alzheimer's drug AR1001 [1]. - HeartCare Medical-B (02160) surged by 8.8% as the company is expected to acquire and restructure MicroPort's cardiac management business, enhancing its product pipeline [1]. Insurance Sector - Insurance stocks continued their upward trend, with New China Life Insurance (01336) rising by 4.47% to reach a new high, and China Life Insurance (02628) increasing by 1.5% [2]. Consumer Sector - 361 Degrees (01361) rose by 6.5%, with institutions expecting strong revenue growth for the full year [3]. - Dreamland (01119) increased by 3.5% after signing a capitalization agreement with Playrix, bringing in a strategic shareholder from the upstream development sector [4]. Semiconductor Sector - Gako Technology-B (01167) surged over 20% as a concerted action party increased its stake by over 60,000 shares, raising its total holding to 25.36% [5]. - Semiconductor stocks collectively declined, with Huahong Semiconductor (01347) down 5.3%, SMIC (00981) down 3.9%, and ASMPT (00522) down 2.74%. Nvidia's order for 300,000 H20 chips and Morgan Stanley's comments on the potential impact of the 520 unlock on local industry sentiment contributed to this decline [5].